Asked to reconcile H1 vs H2 EBITDA margins, given strong innovation and mix should be a tailwind.

Bob VanHimbergen explained gross margin expansion is expected to be 50 bps year-over-year, driven by H2 productivity and volumes, offsetting H1 inflationary pressures. U.S. Pet Health strength, accelerating pricing, and higher-margin innovation will benefit. However, continued investment in DTC for market share gains will impact EBITDA margins in H2. Seasonality also plays a role, with the business being more H1 weighted. “We are going to continue to invest in DTC to drive market share gains. I can tell you there is a very high correlation with data-driven decisions that we see but a high correlation between the DTC spend and the market shares that we've picked up here in Q1 and Q2, particularly in Credelio Quattro.”

Asked for a framework on how much of the $100 million organic growth was driven by Zenrelia and Credelio Quattro.

Bob VanHimbergen stated he wouldn't give specific numbers but highlighted the $340 million innovation revenue from the "Big 6" on a stable base. He noted quality growth across the entire portfolio, with Zenrelia and Quattro leading in the U.S. and Zenrelia and AdTab strong internationally. “I probably won't give you numbers, and we think about this as the basket of innovation growing well. But listen, we saw growth across the entire portfolio, right? So we did see our basket motivation go $340 million. That's on a stable base, again, stable base.”

Asked about the source of Befrena's early success (Zenrelia accounts, corporates) and its worldwide opportunity.

Jeff Simmons confirmed strong demand for Befrena, with expectations more than doubled. Zenrelia's success is pulling Befrena, and 83% of U.S. veterinarians surveyed wanted to use it. Supply is currently gated due to manufacturing ramp-up for monoclonal antibodies, expected to be unconstrained in early 2027. Befrena is seen as a key to unlock more corporate accounts and contribute to Elanco's goal of derm leadership. “Bobby's expectations of demand from Q1 to Q2. It's more than doubled on Befrena. So we're being very careful. We're using a gating demand system because once you start a dog on by front, you're going to want to keep them on.”

ELAN

Elanco (ELAN) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Elanco Q2 FY26 — Strong Innovation-Led Growth and Raised Full-Year Outlook

Elanco delivered robust Q2 FY26 results, driven by strong innovation in U.S. Pet Health and Farm Animal segments, leading to an 8% organic constant currency revenue growth. The company raised its full-year outlook for revenue, adjusted EBITDA, and adjusted EPS, while accelerating net leverage reduction. Management emphasized the durability of the animal health market and the effectiveness of its IPP strategy, despite shifts in pet owner purchasing behaviors.

Highlights

Organic constant currency revenue grew 8%, outperforming the high end of guidance.
U.S. Pet Health and U.S. Farm Animal revenue both increased 11%.
Innovation revenue target raised to $1.25 billion for FY26.
Adjusted EBITDA increased 21% to $288 million.
Net leverage ratio improved to 3.1x, approaching the sub-3x target faster than planned.

Concerns

International Farm Animal organic constant currency growth was 2% due to timing of certain shipments in Q1 2026.
Befrena supply anticipated to reach unconstrained levels only in early 2027 due to high demand.
Operating expenses were up 10% in constant currency, driven by targeted DTC support and R&D.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year organic constant currency revenue growth	6% to 7% high materiality	FY26	High
Full-year revenue	$5.09 billion to $5.4 billion high materiality	FY26	High
Full-year adjusted EBITDA	$1.01 billion to $1.035 billion high materiality	FY26	High
Full-year adjusted EPS	$1.10 to $1.16 high materiality	FY26	High
Year-end net leverage ratio	approximately 3x high materiality	Year-end · FY26	High
Q3 revenue	$1.195 billion to $1.22 billion medium materiality	Q3 · FY26	High
Q3 adjusted EBITDA	$200 million to $250 million medium materiality	Q3 · FY26	High
Q3 adjusted EPS	$0.19 to $0.22 medium materiality	Q3 · FY26	High
Long-term gross margin	60% high materiality	Long-term	High
Long-term net leverage target	2x to 2.5x high materiality	Long-term	High
Innovation revenue	approximately $1.25 billion high materiality	FY26	High
Elanco Ascend adjusted EBITDA savings	$200 million to $250 million high materiality	by 2030 · FY30	High
Next Wave blockbuster potential innovations	5 to 6 high materiality	through 2031 · FY31	High
U.S. Pet Health full-year revenue growth	at least high single-digit medium materiality	Full-year · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Total Pet Health Organic constant currency growth: 11%	—	11%	—	—
U.S. Pet Health Strong momentum in vet and retail channelsLed by Zenrelia and Credelio QuattroSeresto led top line growth in retail OTCAchieved share gains across derm, para, osteoarthritis pain, and vaccines	—	11%	—	—
International Pet Health Organic constant currency growth: 9%Led by Zenrelia, AdTab, and Credelio	—	9%	—	—
Total Farm Animal Organic constant currency growth: 5%	—	5%	—	—
U.S. Farm Animal Broad strength across all three speciesBeef cattle led by Experior	—	11%	—	—
International Farm Animal Organic constant currency growth: 2%Ruminant and poultry contributingImpacted by accelerated shipments to Middle East in Q1 2026Year-to-date growth: 7%	—	2%	—	—
Global Ruminants Organic constant currency growth: 12%Including AHV and FX	—	17%	—	—

ELAN operating KPIs by quarter

ELAN operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2025 Q4 FY25	This call Jun 2026 Q2 FY26	Change vs prior quarter
Reorder rate Zenrelia - US	80%+ We're now in about half of the clinics in the US and the reorder rate is over 80%. Source: earnings call transcript	80%+ That's greater than 60% of the total clinic base with a reorder rate maintained at over 80%. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

Product	Type	Timeline	Details
Befrena	launch	May (ahead of allergy season)
Credelio Quattro	expansion	Q2 FY26

Deals & partnerships

AHP International Acquisition to build on global ruminant success.

Recently closed acquisition, building on global ruminant success.

Risks & headwinds

International Farm Animal shipment timing Q2 FY26

International farm animal grew 2% in organic constant currency.

Mitigation:Year-to-date growth of 7% shows strong underlying fundamentals.

Befrena supply constraints Anticipate supply reaching unconstrained levels in early 2027.

Demand is double the size of our expectations.

Mitigation:Ramping capacity to meet higher customer demand; using a gating demand system.

Inflationary pressures First half FY26

Muted growth from inflationary pressures and the high cost of inventory flowing through in the first half.

Mitigation:Elanco Ascend acceleration and favorable product mix are offsetting; flushed out in H2.

Challenging comparisons for Experior Going forward

Anticipate moderating growth rates against challenging comparisons.

Mitigation:Expect Experior to continue to grow and provide portfolio synergies with multiple levers from extending days of use, continued adoption and price.

Competitive spend to gain share Ongoing

Spend is going up to get share.

Mitigation:Elanco's share of voice and competitiveness has increased with competitive reps, multimedia, and distribution partners.

What to watch in Q3 FY26

Befrena supply ramp-up

Early 2027

Current Gated demand, supply ramping

Target Unconstrained supply

Why it matters

Unlocks significant demand and corporate account penetration for a key derm innovation.

Given the robust demand, we anticipate supply, reaching unconstrained levels in early 2027.

Find out whether ELAN delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked about pricing trends in derm and para given competitive concerns, and how Elanco maintains pricing power.

Jeff Simmons stated the market remains responsible on pricing, allowing price increases with portfolio value and differentiation. Noted a competitor recently took a mid-season price increase. Elanco's U.S. Pet Health pricing accelerated in Q2 and is expected to continue in H2. Competition is increasing spend to gain share, but Elanco's competitive position is stronger due to reps, multimedia, and distribution partners.

“We're seeing no change. If anything, in Q2, it's probably been more responsible. I'll point to just in the last 2 weeks, we've seen a competitor actually mid-season take a map price increase, which shows, hey, they believe that a pet owner is resilient and will spend and that, hey, pricing is not where you're going to get changes.”

asked by Glen Santangelo · answered by Jeffrey Simmons

2 min read 6 chapters

Detailed narrative

Innovation-Driven Growth

Elanco's Q2 performance was significantly boosted by its "Big 6" innovation products, particularly Zenrelia and Credelio Quattro, which contributed $340 million in revenue. The company raised its full-year innovation revenue target to $1.25 billion, reflecting strong market share gains and growth in key global markets. This innovation strategy is seen as a key differentiator in a dynamic market.

Omnichannel Strategy and Pet Health Market Dynamics

Despite concerns about U.S. vet visit volumes, Elanco demonstrated strong growth in U.S. Pet Health (up 11%) through its comprehensive portfolio and omnichannel approach, including vet clinics, online, and retail. Management highlighted a shift in pet owner buying behaviors towards more diverse channels, with vet home delivery growing nearly twice as fast as in-clinic sales, and resilient pet owner spending.

Farm Animal Segment Strength

The Farm Animal segment also showed robust performance, with U.S. Farm Animal up 11% and Global Ruminants up 17% reported. This growth is supported by strong consumer demand for high-quality, sustainable animal protein, reinforcing the long-term value of the farm animal business and the "protein revolution."

Elanco Ascend and Margin Expansion

The Elanco Ascend program is accelerating, contributing to an 80 basis point improvement in adjusted gross margin to 58.1% in Q2. The program, focusing on procurement, pricing, organizational optimization, and automation, is on track to deliver $200 million to $250 million in adjusted EBITDA savings by 2030, supporting a clear path to a 60% long-term gross margin.

Balance Sheet Discipline and Capital Allocation

Strong operational performance and a $90 million net debt reduction led to a half-turn decrease in leverage since the start of the year, reaching 3.1x. The company anticipates a net leverage ratio of approximately 3x by year-end, which will unlock greater capital allocation flexibility towards its long-term target of 2x to 2.5x.

Pipeline Confidence

Elanco expressed increased confidence in its "Next Wave" portfolio, expecting 5 to 6 blockbuster potential innovations through 2031. The R&D team has enhanced the number and value of projects, leveraging AI and strategic partnerships to ensure a consistent flow of high-impact innovations.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.